Prostate Cancer

USC Urology Experts Share Valuable Insight During Prostate Cancer Awareness Month

San Francisco, CA ( -- Prostate cancer is the most common cancer in American men except for skin cancers, according to the American Cancer Society. However, innovations in diagnostics and treatment have made prostate cancer a very treatable disease, with a 98% five-year survival rate.

Over-diagnosed prostate cancer in solid organ recipients: lessons from the last 3 decades.

Prostate cancer (PC) is the most common neoplasia in men. With aging of solid organ transplant recipients (SOTR), its incidence is likely to increase. The aim of this study was to analyze PC screening results retrospectively in renal transplant recipients (RTR), hepatic transplant recipients (HTR) and cardiac transplant recipients (CTR).

Small extracellular vesicles modulated by αVβ3 integrin induce neuroendocrine differentiation in recipient cancer cells.

The ability of small extracellular vesicles (sEVs) to reprogram cancer cells is well established. However, the specific sEV components able to mediate aberrant effects in cancer cells have not been characterized.

Acceptance, Indications And Chances Of Focal Therapy In Localized Prostate Cancer: A Real-World Perspective Of Urologists In Germany.

Focal therapy (FT) became a frequently discussed treatment strategy of localized prostate cancer (PCa), but the acceptance and evaluation of FT by practicing urologists is still unclear.

A 25-item anonymized online questionnaire (SurveyMonkey®) was compiled by the German Society of Residents in Urology (GesRU) Academics prostate cancer working group and sent to the members of the German association of Urology (DGU).

Targeting the BAF complex in advanced prostate cancer.

The BRG1/BRM associated factors (BAF) complex is a chromatin remodeling SWI/SNF which is mutated in 20% of cancers. This complex has many interchangeable subunits which may have oncogenic or tumor suppressor activity in a context-dependent manner.

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.

Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear.

To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients.

Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study.

Magnetic resonance imaging (MRI) targeted biopsy (TBx) of the prostate demonstrated to improve detection rate (DR) of clinically significant prostate cancer (csPCa) in biopsy-naive patients achieving strong level of evidence.

Can postreatment free psa ratio be used to predict adverse outcomes in recurrent prostate cancer?

To assess whether free PSA ratio (FPSAR) at biochemical recurrence (BCR) can predict metastasis, castrate-resistant PCa (CRPC), and cancer-specific survival (CSS), following therapy for localized disease.

Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.

Germline mutations in DNA repair (DR) genes and susceptibility genes CDKN2A and HOXB13 have previously been associated with prostate cancer (PC) incidence and/or progression. However, the role and prevalence of this class of mutations in metastatic PC (mPC) are not fully understood.

Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.

In prostate cancer (PCa) recurring after radical prostatectomy (RP), salvage radiotherapy (SRT) is recommended to be given at PSA <0.5 ng/ml. It has been speculated, that the advantage from early SRT is mainly caused by lead-time bias: Calculating from time of SRT, earlier treatment would per-se result in longer time to event/censoring compared with later treatment, but not extend the interval from RP to post-SRT failure.